CORRECTION

Error in Text Wording and Incorrect Reference: In the Original Investigation titled “Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial,” published in the April 18, 2023, issue of JAMA,1 a wording error occurred. On page 1279 in the Discussion section, the sentence “In FIRE-3, the duration of second-line treatment was substantially longer when the first-line treatment was bevacizumab...” should have stated “In FIRE-3, the duration of second-line treatment was substantially shorter when the first-line treatment was bevacizumab...”. In addition, reference 27 should have been “Modest DP, Stintzing S, von Weikersthal LF, et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3718-3726. doi:10.1200/JCO.2015.61.2887.” Supplement 3 of the article also required changes. The article and supplement have been corrected online.


Incorrect Wording: In the JAMA Patient Page titled “What Is Strabismus?,” published in the March 14, 2023, issue of JAMA,1 a sentence contained incorrect wording. The sentence “Patients with more severe strabismus may be offered 1 or more of the following treatments: glasses, patching of the affected eye...” should have read “Patients with more severe strabismus may be offered 1 or more of the following treatments: glasses, patching of the dominant eye...”. This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editors: Jody W. Zylke, MD, Deputy Editor; Kristin Walter, MD, Senior Editor.